Description
LY2090314 is an inhibitor of glycogen synthase kinase (GSK-3).
| Product Unit Size | Cost | Quantity | Stock |
|---|
LY2090314 is an inhibitor of glycogen synthase kinase (GSK-3).
| Cas No. | 603288-22-8 |
|---|---|
| Purity | ≥98% |
| Formula | C28H25FN6O3 |
| Formula Wt. | 512.53 |
| IUPAC Name | 3-[6-fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]-4-imidazo[1,2-a]pyridin-3-ylpyrrole-2,5-dione |
| Synonym | LY2090314 |
| Solubility | DMSO 100 mg/mL (195.11 mM) Ethanol 2 mg/mL warmed (3.9 mM) Water Insoluble |
| Appearance | Yellow Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos. 2013 Apr;41(4):714-26. PMID: 23305709.
Endogenous peptide hormone fragment, involved i...
Non-depolarizing NMJ blocker; nAChR antagonist....
CysLT1 antagonist.
Benzylisoquinoline alkaloid originally found in...
Semi-synthetic taxane.
Coumarin lactone found in chicory and other pla...
VEGFR inhibitor.
5-HT2A and TRPV1 antagonist, potential α1-adre...
Synthetic taxol synthesis intermediate; microtu...
CDK9 inhibitor.
Microtubule polymerization inhibitor, potential...
AR antagonist.
Statin; HMG-CoA reductase inhibitor.
β2-adrenergic agonist.
Synthetic derivative of selenocyanate.
Endogenous peptide fragment, involved in vasoco...
Mycotoxin.
Endogenous peptide hormone, involved in feeding...
Fluoroquinolone; bacterial DNA gyrase inhibitor...